Zomedica (ZOM) said Monday that it has launched two new canine assays for its Truforma in-clinic biosensor testing platform.
One of the tests detects NT-proBNP in dogs, an indication of conditions such as congestive heart failure, the company said.
Another is used to detect progesterone levels, which can be used to determine optimal breeding dates, timing cesarean sections, and detecting reproductive disorders, the company said.
The test delivery results are available in less than 20 minutes, the company said,
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.